NCT00387257已完成1 期
A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 58
- 试验地点
- 2
- 主要终点
- Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry.
研究概览
简要总结
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects with QTc < 450 msec as measured at screening.
排除标准
- •History of asthma.
结局指标
主要结局
Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry.
时间窗: on Day 35 (or 21 days post last dose) as determine by optical aggregometry
次要结局
- Collagen EC50 values on Day 1 and Day 14 as determined by optical aggregometry Plasma Lp-PLA2 activity Clinical safety data Concentrations of rilapladib and SB-664601.(on Day 1 and Day 14 as determined by optical aggregometry)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy SubjectsJoint PainNCT05212259Vedic Lifesciences Pvt. Ltd.375
已完成
3 期
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT00527605GlaxoSmithKline253
已完成
2 期
RN624 For Pain Of Post-Herpetic NeuralgiaNeuralgia, PostherpeticNCT00568321Pfizer99
已完成
不适用
A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic IndividualsOverweightPre DiabetesNCT06440213Nuritas Ltd132
已完成
2 期
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight SubjectsOverweightObesityNCT00785408AstraZeneca273